<DOC>
	<DOCNO>NCT01495364</DOCNO>
	<brief_summary>This study ass safety efficacy intracoronary artery administer autologous bone marrow derive stem cell subject post ST segment elevation myocardial infarction ( STEMI ) . This assess evaluate compare autologous stem cell treatment group control group term occurrence AE 's , SAE 's Major Adverse Cardiac Events ( MACE ) , change myocardial perfusion ( RTSS ) measure quantitatively gate single photon emission compute tomography myocardial perfusion imaging ( gate SPECT MPI ) , secondary endpoint LVEF measure cardiac MRI addition endpoint .</brief_summary>
	<brief_title>NBS10 ( Also Known AMR-001 ) Versus Placebo Post ST Segment Elevation Myocardial Infarction</brief_title>
	<detailed_description>Efficacy endpoint 6 month . Clinical endpoint safety measure 36 month .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . Age 18 year old . 2 . Acute ST elevation myocardial infarction meeting ACC/AHA criterion , symptom chest pain within 3 day admission . Criteria include ( ST elevation &gt; 1mm limb lead 2 mm two precordial lead , increased level troponin , CPK MB ) . Chest pain syndrome extend 3 day prior admission course consistent transient/intermittent ischemia rather symptoms continuous suggest ongoing infarction extend beyond 3 day . 3 . Successful stent placement reperfusion within 3 day chest pain onset TIMI Flow score 2 3 infarct relate artery ( IRA ) &lt; 20 % stenosis revascularization . 4 . Wall motion abnormality associate target lesion 5 . NYHA heart failure class I , II III . 6 . Study entry LVEF &lt; 48 % determine CMR sooner 96 hour stent placement . 7 . Able provide inform write consent willing participate require study followup assessment . 8 . Subjects must INR ≤ 2.0 within 2 day bone marrow collection . 9 . Subjects must Hgb ≥ 10 grams/dL , WBC ≥ 3500 cells/mm3 , platelet count ≥ 100,000 cells/mm3 , serum creatinine ≤ 2.5 , total bilirubin ≤ 2.0 within 7 day bone marrow collection end screen phase . 10 . Expected survival least one year . 11 . Females child bear potential agree use birth control ( barrier method accept ) one month post bone marrow harvest . EXCLUSION CRITERIA 1 . Continuous/ongoing chest pain unremitting unresponsive nitroglycerin rest persist 4 day stent placement . If chest pain syndrome transient and/or intermittent even begin 3 day prior admission patient exclude . 2 . Subjects cardiogenic shock ( systolic pressure &lt; 80mm/Hg , vasopressor , intraaortic counterpulsation ) time consent . Subjects recover cardiogenic shock time consent eligible . 3 . Subjects unable receive antiplatelet agent ( e.g . aspirin , clopidogrel , ticlopidine , prasugrel , etc ) . 4 . Subjects receive warfarin INR &gt; 2 major bleed require active transfusion support . 5 . Subjects require continuous anticoagulation time bone marrow harvest schedule , heparin must discontinue 4 hour prior 24 hour bone marrow harvest procedure . ( See Appendix VII . ) 6 . Subjects severe cardiac valvular disease expect undergo surgery within 1 year . 7 . Subjects know severe immunodeficiency state ( AIDS ) . 8 . Cirrhosis require active medical management . 9 . Malignancy require active treatment ( except basal cell skin cancer ) . 10 . Subjects document active alcohol /or substance abuse . 11 . Females child bear potential unless pregnancy test negative within 7 day minibone marrow harvest . 12 . Reocclusion IRA prior infusion procedure . 13 . Planned revascularization intervention next 6 month ( A second PCI perform do prior qualify CMR least 96 hour post primary PCI ) . 14 . Participation ongoing investigational trial . 15 . Active suspect bacterial infection require systemic intravenous antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>STEMI</keyword>
</DOC>